SEC EDGARJUN 52 min read$INSM

Lewis William sold $778K of INSM

Lewis William (Chair and CEO) sold 7,605 shares of INSMED Inc (INSM) at $102.27 ($0.78M total) on 2026-06-03.

Original reporting

SEC EDGAR · Lewis William

Published Jun 5, 2026, 8:12 PM UTC

Analysis

alphai AI DeskAI-generated

Added to alphai Jun 5, 2026, 8:14 PM UTC. Informational, not investment advice.

How this was made

alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About alphai AI Desk Scoring methodology Report an issue

alphai market briefInsider activity

Primary signal

$INSM

Neutral

medium confidence

Mentioned

$INSM

Relevance

6/10

alphai data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$INSMNeutralLow

Why it matters

Traders may briefly reassess sentiment around management alignment, but without additional disclosures (guidance, trial results, financing, or legal updates) the impact is likely limited to positioning/flow rather than fundamentals.

Market read

A disclosed insider sale can influence short-term sentiment, but it is not a standalone fundamental catalyst.

What to watch

The filing doesn’t state reasons for the sale, and the post-transaction share count remains sizable, which can mute bearish interpretation.

Relevance 6/10Novelty 6/10Timing: Filed today; reflects sale executed 2026-06-03.

Background

The article is an SEC Form 4 insider transaction disclosure for INSMED Inc, reporting an open-market sale by the CEO/Chair.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$INSMNeutralMedium confidence

Context

INSMED CEO/Chair Lewis William sold 7,605 shares in an open-market transaction disclosed on SEC Form 4.

Expected impact

Low probability of a sustained price move; any reaction is likely short-lived unless accompanied by other news.

Evidence & confidence

The filing is an ownership-change disclosure with no 10b5-1 plan and no accompanying company-specific operational update, limiting causal linkage to fundamentals.

Market effects

Sector

Minimal; this is company-specific insider activity with no stated read-across to peers.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Absence of a 10b5-1 plan doesn’t necessarily signal negative fundamentals; sales can be for diversification, taxes, or planned liquidity needs.

Key entities

issuer
INSMED Inc
Subject of the SEC Form 4 insider sale by its Chair and CEO.
insider
Lewis William
Chair and CEO who sold 7,605 shares at $102.2700 on 2026-06-03.

Read at source ← All news

SEP 2

$INSMHighAI 8/10

Insmed’s (INSM) New Drug Launch Is Reshaping The Whole Business

Insmed (INSM) reported Q2 2026 revenue of $425.5M, up 296% YoY, with net loss narrowing to $13.2M. BRINSUPRI sales reached $309.2M, up 49% QoQ. The company raised full-year BRINSUPRI guidance to $1.25B-$1.40B. Insmed also increased its peak revenue estimate for lead programs to over $14B. Expenses rose due to commercial buildout and R&D spending.

insidermonkey.com2 min

SEP 1

$INSMMedAI 8/10

Is Insmed (INSM) Undervalued Following Japan Approval For BRINSUPRI?

Insmed (INSM) received approval for BRINSUPRI in Japan, adding to U.S. and European clearances. Shares rose 2.78% to $121.84, with a 30-day return of 23.57% but a YTD decline of 31.21%. Analysts suggest a fair value of $197.14, indicating potential undervaluation, but risks include approval delays and reimbursement challenges.

simplywall.st3 min

AUG 28

$GILDMedAI 8/10

Weekly Buzz: Gilead Sciences, Roivant Sciences Win FDA Nod; Biohaven, Eli Lilly Strike Deal; Spyre Therapeutics Misses Monotherapy Goal

Gilead (GILD) and Roivant (ROIV) received FDA approvals for Bixlenvo and LISRAYA, respectively. Johnson & Johnson (JNJ) also gained approval for IMAAVY. Biohaven (BHVN) and Eli Lilly (LLY) advanced partnerships. Spyre Therapeutics missed a clinical trial goal. Key stocks: GILD +0.52%, ROIV +2.26%, JNJ -1.57%.

finanznachrichten.de3 min

AUG 24

$INSMHighAI 8/10

Mizuho raises Insmed stock price target to $195 on Japan approval

Mizuho raised its price target for Insmed (INSM) to $195, citing Japan's approval of Brinsupri. The stock trades at $123.98, with a market cap of $27.1B. Insmed reported strong Q2 2026 revenue, raising guidance for Brinsupri and TPIP. Analysts maintain a strong buy rating, with upward earnings revisions.

investing.com2 min

AUG 24

$INSMHighAI 9/10

BRINSUPRI® (brensocatib) Approved by Japan's Ministry of Health, Labour and Welfare for the Treatment of Patients With Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease

Insmed Inc. (INSM) announced Japan's approval of BRINSUPRI® (brensocatib) for treating non-cystic fibrosis bronchiectasis (NCFB) in adults and pediatric patients 12+. The approval is based on Phase 3 ASPEN study results showing reduced pulmonary exacerbations and lower lung function decline. BRINSUPRI is now approved in the U.S., Europe, and Japan.

prnewswire.com2 min

AUG 19

$INSMMed

How Insmed’s Sharply Narrowed Q2 2026 Net Loss At Insmed (INSM) Has Changed Its Investment Story

Insmed Inc. (INSM) reported a sharply narrowed net loss of $13.24M in Q2 2026, down from $321.69M a year earlier, with loss per share at $0.06 vs. $1.70. The company's H1 2026 net loss also improved to $176.81M from $578.27M, indicating lower cash burn. Insmed's investment narrative focuses on its respiratory portfolio, particularly brensocatib, with guidance projecting $1B in 2026 BRINSUPRI revenue and $450M-$470M from ARIKAYCE. The company aims for $4.1B revenue and $1B earnings by 2029, requi

simplywall.st2 min